LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

Study Overview

Study 19 was a randomised, double-blind, placebo-controlled phase II clinical trial.2

In Study 19, Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study population.2

Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study population.
Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study population.

A retrospective analysis was conducted on a pre-defined subgroup of patients with BRCA mutations. This is included 51% of patients N=136.3

**Platinum-sensitive defined by a relapse-free period of ~6 months following a response to the final dose of platinum-based chemotherapy treatment.